Zentalis Pharmaceuticals, Inc.
ZNTL
$1.63
-$0.12-6.86%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 26.87M | 26.87M | 67.43M | 40.56M | 40.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.87M | 26.87M | 67.43M | 40.56M | 40.56M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 26.87M | 26.87M | 67.43M | 40.56M | 40.56M |
| SG&A Expenses | 72.49M | 81.96M | 87.12M | 63.48M | 64.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 197.14M | 227.39M | 254.88M | 249.83M | 261.11M |
| Operating Income | -170.28M | -200.52M | -187.46M | -209.27M | -220.55M |
| Income Before Tax | -163.02M | -224.15M | -165.69M | -179.09M | -194.41M |
| Income Tax Expenses | -232.00K | 34.00K | 177.00K | 247.00K | 305.00K |
| Earnings from Continuing Operations | -162.78 | -224.19 | -165.87 | -179.33 | -194.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | 0.00 | 28.00K | 50.00K | 62.00K |
| Net Income | -162.78M | -224.19M | -165.84M | -179.28M | -194.65M |
| EBIT | -170.28M | -200.52M | -187.46M | -209.27M | -220.55M |
| EBITDA | -169.22M | -199.29M | -186.17M | -207.96M | -219.22M |
| EPS Basic | -2.28 | -3.15 | -2.33 | -2.53 | -2.75 |
| Normalized Basic EPS | -1.54 | -1.89 | -1.47 | -1.42 | -1.55 |
| EPS Diluted | -2.28 | -3.15 | -2.33 | -2.53 | -2.75 |
| Normalized Diluted EPS | -1.54 | -1.89 | -1.47 | -1.42 | -1.55 |
| Average Basic Shares Outstanding | 286.05M | 285.10M | 284.32M | 283.88M | 283.38M |
| Average Diluted Shares Outstanding | 286.05M | 285.10M | 284.61M | 284.18M | 283.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |